pith. sign in

arxiv: 2605.21645 · v1 · pith:HQV2FLUFnew · submitted 2026-05-20 · 💻 cs.AI · cs.DB

AOP-Wiki EMOD 3.0: Data Model Expansions and Content Evaluation Framework for Using Agentic AI to Improve Integration between AOPs and New Approach Methodologies (NAMs)

Virginia K. Hench , J. Harry Caufield , Sierra A.T. Moxon , Jason M. O'Brien , Stephen W. Edwards This is my paper

Pith reviewed 2026-05-22 09:16 UTC · model grok-4.3

classification 💻 cs.AI cs.DB
keywords Adverse Outcome PathwaysAOP-WikiData Model ExpansionNew Approach MethodologiesAgentic AIRegulatory ScienceFAIR PrinciplesQuantitative AOPs
0
0 comments X

The pith

AOP-Wiki EMOD 3.0 expands the data model to support agentic AI integration of adverse outcome pathways with new approach methodologies.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper presents AOP-Wiki EMOD 3.0 as a concrete prototype that expands the data model of the global repository for adverse outcome pathways. Current constraints in the existing data model and infrastructure limit continued AOP growth and evolution. The expansions target internal quality improvement, evidence structuring to boost FAIRness and AI-readiness, and tighter links between AOPs and NAMs. A sympathetic reader would care because AOPs help contextualize lab and computer-based alternatives to animal testing, and this change could advance their use in regulatory science plus biomedical and One Health applications. The work lays groundwork for AI to generate AOPs and produce quantitative versions of them.

Core claim

AOP-Wiki EMOD 3.0 concretely demonstrates data model expansions and the vision for transforming the AOP-Wiki to better serve regulatory science and emergent use of AOPs in biomedical and One Health contexts. It focuses on solutions for AOP-Wiki internal quality improvement, evidence structuring to enhance AOP FAIRness and AI-readiness, and improved integration between the AOP framework and NAMs to better serve next generation risk assessment, while laying a foundation to support computationally-generated AOPs and quantitative AOPs.

What carries the argument

EMOD 3.0 data model expansions that enable quality improvement, evidence structuring for FAIRness and AI-readiness, and AOP-NAM integration.

If this is right

  • Supports computationally-generated AOPs.
  • Enables quantitative AOPs.
  • Improves AOP-Wiki internal quality and evidence structuring.
  • Enhances AOP FAIRness and AI-readiness.
  • Strengthens integration between AOPs and NAMs for next-generation risk assessment.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • The model may allow AI agents to aggregate and structure AOP-relevant information across biological scales more systematically.
  • It could extend multi-scale causal modeling from chemical regulation into broader systems biology applications.
  • Successful adoption might accelerate replacement of animal tests by making NAM data more readily usable within established AOP logic.

Load-bearing premise

Constraints in the current AOP-Wiki data model and application infrastructure limit continued AOP growth and evolution, and the proposed expansions will enable better integration with NAMs and agentic AI without introducing incompatibilities.

What would settle it

After deploying EMOD 3.0, measure whether AI systems can generate valid new AOPs or quantitative AOPs that integrate directly with existing NAM data sets without compatibility failures or loss of causal structure.

read the original abstract

Adverse Outcome Pathways (AOP) are logic models that causally link biological mechanisms that can be measured in a lab to adverse outcomes, relevant to chemical regulatory endpoints. AOPs contextualize new approach methodologies (NAMs), in vitro and in silico methods used as alternatives to animal testing and the sequential events in an AOP serve as multi-scale models spanning biological scales. The AOP-Wiki serves as the global repository for AOPs. While the AOP-Wiki has played a central role in AOP expansion over the past decade, constraints within the current data model and application infrastructure limit the AOP-Wiki from supporting continued AOP growth and evolution. Yet, the transformative power of agentic AI has re-invigorated AOP-Wiki data modernization efforts at a time when core AOP principles can be harnessed to inform use of AI for aggregating and structuring AOP-relevant information. Seizing upon this momentum, we present AOP-Wiki EMOD 3.0, the third in a series of evidence model prototypes, which concretely demonstrates data model expansions and our vision for how the AOP-Wiki might be transformed to better serve regulatory science and emergent use of AOPs in biomedical and One Health contexts. We aim to lay a foundation to support computationally-generated AOPs and quantitative AOPs (qAOPs) by focussing on solutions for AOP-Wiki internal quality improvement, evidence structuring to enhance AOP FAIRness and AI-readiness, and improved integration between the AOP framework and NAMs to better serve next generation risk assessment.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Referee Report

2 major / 2 minor

Summary. The manuscript presents AOP-Wiki EMOD 3.0, the third evidence model prototype, which demonstrates data model expansions for the AOP-Wiki repository. It addresses constraints in the current data model and infrastructure to support continued AOP growth, evidence structuring for improved FAIRness and AI-readiness, better integration with New Approach Methodologies (NAMs), and foundations for computationally-generated AOPs and quantitative AOPs (qAOPs) in regulatory science, biomedical, and One Health contexts, leveraging agentic AI.

Significance. If the proposed expansions prove effective and compatible, this work could provide a timely foundation for modernizing the AOP-Wiki to accommodate growing content and emerging AI-driven applications in toxicology and risk assessment. The emphasis on internal quality improvement and NAM integration aligns with current needs in regulatory science, though the absence of empirical validation limits immediate impact assessment.

major comments (2)
  1. [Data model expansions and content evaluation framework] The manuscript describes the EMOD 3.0 data model expansions and vision for AOP-Wiki transformation but does not report results from importing or restructuring existing AOP entries, nor any evaluation of whether new fields preserve causal logic or support quantitative extensions. This is load-bearing for the central claim that the expansions resolve infrastructure constraints and enable NAM/AI integration without incompatibilities.
  2. [Evidence structuring and integration sections] No migration tests or compatibility checks with current AOP-Wiki content are presented, leaving the premise that the changes will be effective and non-disruptive untested. This directly affects the claim that EMOD 3.0 lays a foundation for computationally-generated AOPs and qAOPs.
minor comments (2)
  1. [Abstract] The abstract outlines goals at a high level but could include one or two concrete examples of new data fields or structures to improve accessibility for readers unfamiliar with AOP-Wiki internals.
  2. [Introduction and methods] Notation for new model elements (e.g., expanded evidence fields) should be defined more explicitly early in the manuscript to avoid ambiguity when discussing AI-readiness and FAIR principles.

Simulated Author's Rebuttal

2 responses · 0 unresolved

We thank the referee for their thoughtful and constructive review of our manuscript describing AOP-Wiki EMOD 3.0. The comments correctly identify the current scope as primarily a design and framework proposal. We address each point below and indicate planned revisions to clarify limitations and strengthen the presentation.

read point-by-point responses

  1. Referee: The manuscript describes the EMOD 3.0 data model expansions and vision for AOP-Wiki transformation but does not report results from importing or restructuring existing AOP entries, nor any evaluation of whether new fields preserve causal logic or support quantitative extensions. This is load-bearing for the central claim that the expansions resolve infrastructure constraints and enable NAM/AI integration without incompatibilities.

    Authors: We agree that the manuscript does not include results from importing or restructuring existing AOP entries or direct evaluations of causal logic preservation. This reflects the manuscript's focus on defining the expanded data model and content evaluation framework as a foundational prototype rather than a completed implementation study. In revision we will add explicit discussion of how the new fields are structured to maintain core AOP causal logic and to accommodate quantitative extensions, along with a clear statement of the evaluation roadmap for future work. This will better contextualize the claims without overstating current empirical coverage. revision: partial

  2. Referee: No migration tests or compatibility checks with current AOP-Wiki content are presented, leaving the premise that the changes will be effective and non-disruptive untested. This directly affects the claim that EMOD 3.0 lays a foundation for computationally-generated AOPs and qAOPs.

    Authors: We concur that migration tests and compatibility checks are absent and would strengthen confidence in non-disruptiveness. The manuscript emphasizes the conceptual design intended to overcome identified infrastructure constraints while supporting future computational and quantitative AOP development. We will revise the evidence structuring and integration sections to include a more detailed description of backward-compatibility considerations and how the framework is intended to enable incremental adoption, thereby clarifying the foundation-laying role without implying completed validation. revision: partial

Circularity Check

0 steps flagged

No significant circularity; descriptive proposal with no derivations or self-referential reductions

full rationale

The paper is a forward-looking description of data model expansions for AOP-Wiki EMOD 3.0, including a vision for AI integration and NAM support. No equations, fitted parameters, predictions, or derivation chains are present that could reduce to inputs by construction. The mention of being the 'third in a series' provides context but does not serve as a load-bearing self-citation for the central claims about expansions or effectiveness. The content stands as an independent proposal without self-definitional loops, renamed results, or ansatz smuggling. This is a normal non-finding for a framework paper.

Axiom & Free-Parameter Ledger

0 free parameters · 2 axioms · 0 invented entities

The work rests on established domain concepts in AOPs and regulatory science without introducing new physical entities, fitted parameters, or ad-hoc axioms beyond the stated need for modernization.

axioms (2)
  • domain assumption AOPs are logic models that causally link biological mechanisms measurable in a lab to adverse outcomes relevant to chemical regulatory endpoints.
    This definition is invoked at the start of the abstract as the foundational concept for the entire framework.
  • domain assumption Constraints within the current data model and application infrastructure limit the AOP-Wiki from supporting continued AOP growth and evolution.
    This premise is stated directly as the motivation for developing EMOD 3.0.

pith-pipeline@v0.9.0 · 5845 in / 1647 out tokens · 54303 ms · 2026-05-22T09:16:54.491387+00:00 · methodology

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Lean theorems connected to this paper

Citations machine-checked in the Pith Canon. Every link opens the source theorem in the public Lean library.

What do these tags mean?
matches
The paper's claim is directly supported by a theorem in the formal canon.
supports
The theorem supports part of the paper's argument, but the paper may add assumptions or extra steps.
extends
The paper goes beyond the formal theorem; the theorem is a base layer rather than the whole result.
uses
The paper appears to rely on the theorem as machinery.
contradicts
The paper's claim conflicts with a theorem or certificate in the canon.
unclear
Pith found a possible connection, but the passage is too broad, indirect, or ambiguous to say the theorem truly supports the claim.

Reference graph

Works this paper leans on

48 extracted references · 48 canonical work pages

  1. [1]

    AOP-Wiki [Internet]

    Society for Advancement of AOPs. AOP-Wiki [Internet]. [cited 2025 Aug 24]. AOP-Wiki Home Page. Available from: aopwiki.org

    work page 2025

  2. [2]

    AOP-Wiki - 2013 Beta Release Notes [Internet]

    Edwards SW. AOP-Wiki - 2013 Beta Release Notes [Internet]. [cited 2026 May 18]. Available from: https://aopwiki.org/info_pages/3#Beta%20Release%20(6/30/2013)

    work page 2013

  3. [3]

    AOP-Wiki - Notes for Release 1.0 (9/28/2014) [Internet]

    Edwards SW. AOP-Wiki - Notes for Release 1.0 (9/28/2014) [Internet]. [cited 2026 May 18]. Available from: https://aopwiki.org/info_pages/3#Release%201.0%20(9/28/2014)

    work page 2014

  4. [4]

    Advancing the Computability of AOPs: Updates on AOP-Wiki Releases 2.7 and 2.8 [Poster] [Internet]

    Hench G, Karschnik T, Williams D, Abedini J, Delrue N, Sachana M, et al. Advancing the Computability of AOPs: Updates on AOP-Wiki Releases 2.7 and 2.8 [Poster] [Internet]. Poster presented at: ISMB. 2025 Aug 9 [cited 2025 Aug 24]; Liverpool, UK. Available from: 10.6084/m9.figshare.29875760.v1 doi:10.6084/m9.figshare.29875760.v1

    work page doi:10.6084/m9.figshare.29875760.v1 2025

  5. [5]

    Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment

    Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, et al. Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem. 2010;29(3):730–41. Located at: 20821501. doi:10.1002/etc.34

    work page doi:10.1002/etc.34 2010

  6. [6]

    A high-level overview of the OECD AOP Development Programme

    Chauhan V, Hamada N, Wilkins R, Garnier-Laplace J, Laurier D, Beaton D, et al. A high-level overview of the OECD AOP Development Programme. Int J Radiat Biol. 2022 Dec 2;98(12):1704–13. doi:10.1080/09553002.2022.2110311 PubMed PMID: 35938955

    work page doi:10.1080/09553002.2022.2110311 2022

  7. [7]

    Guidance Document for the scientific review of Adverse Outcome Pathways

    OECD. Guidance Document for the scientific review of Adverse Outcome Pathways. OECD Ser Test Assess. 2021 Dec 7. doi:10.1787/a6bec14b-en

    work page doi:10.1787/a6bec14b-en 2021

  8. [8]

    Update from the Society for the Advancement of Adverse Outcome Pathways [presentation] [Internet]

    Villeneuve D. Update from the Society for the Advancement of Adverse Outcome Pathways [presentation] [Internet]. Presentation presented at: OECD Advisory Group on Emerging Science in Chemicals Assessment. The United States Environmental Protection Agency; 2023 Jun 29 [cited 2026 Jan 20]. Available from: doi.org/10.23645/epacomptox.23596401.v1 doi:doi.org/...

    work page doi:10.23645/epacomptox.23596401.v1 2023

  9. [9]

    [cited 2024 Sep 2]

    OECD [Internet]. [cited 2024 Sep 2]. Integrated Approaches to Testing and Assessment (IATA). Available from: https://www.oecd.org/en/topics/sub-issues/assessment-of-chemicals/integrated-approaches-to-testing-and-assessment.html

    work page 2024

  10. [10]

    Guidance Document for the Use of Adverse Outcome Pathways in Developing Integrated Approaches to Testing and Assessment (IATA) [Internet]

    OECD. Guidance Document for the Use of Adverse Outcome Pathways in Developing Integrated Approaches to Testing and Assessment (IATA) [Internet]. Paris: Organisation for Economic Co-operation and Development; 2017 [cited 2022 Mar 20]. Available from: https://www.oecd-ilibrary.org/environment/guidance-document-for-the-use-of-adverse-outcome-pathways-in-deve...

    work page 2017

  11. [11]

    The skin sensitization adverse outcome pathway: exploring the role of mechanistic understanding for higher tier risk assessment

    Aleksic M, Rajagopal R, de-Ávila R, Spriggs S, Gilmour N. The skin sensitization adverse outcome pathway: exploring the role of mechanistic understanding for higher tier risk assessment. Crit Rev Toxicol. 2024 Feb 7;54(2):69–91. doi:10.1080/10408444.2024.2308816

    work page doi:10.1080/10408444.2024.2308816 2024

  12. [12]

    Radiation Adverse Outcome pathways (AOPs): examining priority questions from an international horizon-style exercise

    Chauhan V, Beaton D, Tollefsen KE, Preston J, Burtt JJ, Leblanc J, et al. Radiation Adverse Outcome pathways (AOPs): examining priority questions from an international horizon-style exercise. Int J Radiat Biol. 2024 Jul 2;100(7):982–95. doi:10.1080/09553002.2024.2348072 PubMed PMID: 38718325

    work page doi:10.1080/09553002.2024.2348072 2024

  13. [13]

    A high-level overview of the OECD AOP Development Programme

    Burtt JJ, Leblanc J, Randhawa K, Ivanova A, Rudd MA, Wilkins R, et al. Radiation adverse outcome pathways (AOPs) are on the horizon: advancing radiation protection through an international Horizon-Style exercise. Int J Radiat Biol. 2022 Dec 2;98(12):1763–76. doi:10.1080/09553002.2022.2121439 PubMed PMID: 36067511

    work page doi:10.1080/09553002.2022.2121439 2022

  14. [14]

    Data-driven derivation of an adverse outcome pathway linking vascular endothelial growth factor receptor (VEGFR), endocrine disruption, and atherosclerosis

    Ehrlich D, Krishna S, Kleinstreuer N. Data-driven derivation of an adverse outcome pathway linking vascular endothelial growth factor receptor (VEGFR), endocrine disruption, and atherosclerosis. ALTEX - Altern Anim Exp. 2024 Oct 22;41(4):617–32. doi:10.14573/altex.2403211

    work page doi:10.14573/altex.2403211 2024

  15. [15]

    Accelerating AOP Development in the AOP-Wiki with AI: A Practical Road Map for the Community

    Song Y, Kumar V, Tanabe S, Villeneuve DL, Wittwehr C. Accelerating AOP Development in the AOP-Wiki with AI: A Practical Road Map for the Community. Environ Sci Technol. 2026 May 18. doi:10.1021/acs.est.6c05148

    work page doi:10.1021/acs.est.6c05148 2026

  16. [16]

    AOP-Wiki Release Notes [Internet]

    Society for Advancement of AOPs. AOP-Wiki Release Notes [Internet]. [cited 2026 Apr 23]. Available from: https://aopwiki.org/info_pages/3

    work page 2026

  17. [18]

    Enhancing the FAIRness (Findability, Accessibility, Interoperability, and Reusability) of the AOP-Wiki [Internet]

    Hench G, Edwards SW, Karshnik T, Villeneuve D, O’Brien JM, Wittwehr C. Enhancing the FAIRness (Findability, Accessibility, Interoperability, and Reusability) of the AOP-Wiki [Internet]. 2023 Mar 19. doi:10.6084/m9.figshare.26153326.v1

    work page doi:10.6084/m9.figshare.26153326.v1 2023

  18. [19]

    Integrated Application and Transformation of the Adverse Outcome Pathway (AOP) Framework for Modeling Evidence and Advancing New Approach Methodologies (NAMs) [Poster] [Internet]

    Hench VK, Edwards S, Lynn SG, Markey K, Villeneuve D. Integrated Application and Transformation of the Adverse Outcome Pathway (AOP) Framework for Modeling Evidence and Advancing New Approach Methodologies (NAMs) [Poster] [Internet]. Poster presented at: Intelligent Systems for Molecular Biology. 2024 Jul 15 [cited 2025 Aug 23]; Montreal, Canada. Availabl...

    work page doi:10.6084/m9.figshare.26390980.v1 2024

  19. [20]

    Adverse Outcome Pathways and the Paradox of Complex Simplicity

    Knapen D. Adverse Outcome Pathways and the Paradox of Complex Simplicity. Environ Toxicol Chem. 2021;40(11):2950–2. doi:10.1002/etc.5205

    work page doi:10.1002/etc.5205 2021

  20. [21]

    Rethinking the Data Model for the AOP Knowledgebase [Internet]

    Edwards S. Rethinking the Data Model for the AOP Knowledgebase [Internet]. 2022 Jul [cited 2025 Sep 1]; NTP Virtual Workshop. Available from: 10.5281/zenodo.17021226 doi:10.5281/zenodo.17021226

    work page doi:10.5281/zenodo.17021226 2022

  21. [22]

    AOP-Wiki 3.0 Series Recap: What we heard and next steps [Internet]

    Hench G. AOP-Wiki 3.0 Series Recap: What we heard and next steps [Internet]. 2023 Sep 28 [cited 2025 Aug 31]. Available from: 10.5281/zenodo.16690242 doi:10.5281/zenodo.16690242

    work page doi:10.5281/zenodo.16690242 2023

  22. [23]

    Why adverse outcome pathways need to be FAIR

    Wittwehr C, Clerbaux LA, Edwards S, Angrish M, Mortensen H, Carusi A, et al. Why adverse outcome pathways need to be FAIR. ALTEX - Altern Anim Exp. 2024 Jan 9;41(1):1. doi:10.14573/altex.2307131

    work page doi:10.14573/altex.2307131 2024

  23. [24]

    JRC Publications Repository [Internet]

    Wittwehr C, Audouze K, Burgdorf T, Clerbaux LA, Coerek E, Demuynck E, et al. JRC Publications Repository [Internet]. 2025 [cited 2025 Aug 23]. SKIG Report 2023-2024. Available from: 10.2760/7749010 doi:10.2760/7749010

    work page doi:10.2760/7749010 2025

  24. [25]

    The FAIR AOP roadmap for 2025: Advancing findability, accessibility, interoperability, and re-usability of adverse outcome pathways

    Mortensen HM, Gromelski M, Hench G, Martens M, Wittwehr C, Kumar S, et al. The FAIR AOP roadmap for 2025: Advancing findability, accessibility, interoperability, and re-usability of adverse outcome pathways. Comput Toxicol. 2025 Sep 1;35:100368. doi:10.1016/j.comtox.2025.100368

    work page doi:10.1016/j.comtox.2025.100368 2025

  25. [26]

    Methods2AOP: An International Collaboration Advancing AOP Key Event Descriptions [Internet]

    Karmaus A. Methods2AOP: An International Collaboration Advancing AOP Key Event Descriptions [Internet]. 2023 Aug 28 [cited 2025 Sep 1]. Available from: 10.5281/zenodo.17023859 doi:10.5281/zenodo.17023859

    work page doi:10.5281/zenodo.17023859 2023

  26. [27]

    Methods2AOP: A Collaboration to Strengthen the Integration of Test Methods into the Adverse Outcome Pathway Framework [Internet]

    Karmaus AL, Bisson W, Braeuning A, Chang X, Clerbaux LA, Filipovska J, et al. Methods2AOP: A Collaboration to Strengthen the Integration of Test Methods into the Adverse Outcome Pathway Framework [Internet]. F1000Research; 2026 [cited 2026 Apr 25]. Available from: https://f1000research.com/articles/14-1375 doi:10.12688/f1000research.172881.2

    work page doi:10.12688/f1000research.172881.2 2026

  27. [28]

    Creating a Structured AOP Knowledgebase via Ontology-Based Annotations

    Ives C, Campia I, Wang RL, Wittwehr C, Edwards S. Creating a Structured AOP Knowledgebase via Ontology-Based Annotations. Appl Vitro Toxicol. 2017 Dec 1;3(4):298–311. doi:10.1089/aivt.2017.0017 PubMed PMID: 30057931; PubMed Central PMCID: PMC6060416

    work page doi:10.1089/aivt.2017.0017 2017

  28. [29]

    AOP-Wiki Release 2.2 (2018) [Internet]

    Edwards SW. AOP-Wiki Release 2.2 (2018) [Internet]. [cited 2026 May 19]. Available from: https://aopwiki.org/info_pages/3#Release%202.2%20(1/28/2018)

    work page 2018

  29. [30]

    De-risking seizure liability: integrating adverse outcome pathways (AOPs), new approach methodologies (NAMs), and in silico approaches while highlighting knowledge gaps

    Behl M, Karmaus A, Rao M, Lane T, Harris J, Sachs C, et al. De-risking seizure liability: integrating adverse outcome pathways (AOPs), new approach methodologies (NAMs), and in silico approaches while highlighting knowledge gaps. Toxicol Sci. 2025 Jul 25. doi:10.1093/toxsci/kfaf109

    work page doi:10.1093/toxsci/kfaf109 2025

  30. [31]

    Toxicogenomics Data for Chemical Safety Assessment and Development of New Approach Methodologies: An Adverse Outcome Pathway-Based Approach

    Saarimäki LA, Morikka J, Pavel A, Korpilähde S, del Giudice G, Federico A, et al. Toxicogenomics Data for Chemical Safety Assessment and Development of New Approach Methodologies: An Adverse Outcome Pathway-Based Approach. Adv Sci. 2023;10(2):2203984. doi:10.1002/advs.202203984

    work page doi:10.1002/advs.202203984 2023

  31. [32]

    AOP-Wiki v2.7 [Internet]. 2025. AOP-Wiki Third Party Tools. Available from: aopwiki.org/info_pages/8

    work page 2025

  32. [33]

    AOPGraphExplorer: Explore, Analyze, and Visualize AOP-Wiki Data Easily [Internet]

    Ali A, Connect (Switzerland) E. AOPGraphExplorer: Explore, Analyze, and Visualize AOP-Wiki Data Easily [Internet]. Zenodo; 2025 [cited 2025 Sep 7]. Available from: zenodo.org/records/15323478 doi:10.5281/zenodo.15323478

    work page doi:10.5281/zenodo.15323478 2025

  33. [34]

    ToxMCP: Guardrailed, Auditable Agentic Workflows for Computational Toxicology via the Model Context Protocol [Internet]

    Djidrovski I. ToxMCP: Guardrailed, Auditable Agentic Workflows for Computational Toxicology via the Model Context Protocol [Internet]. bioRxiv; 2026 [cited 2026 May 12]. p. 2026.02.06.703989. Available from: https://www.biorxiv.org/content/10.64898/2026.02.06.703989v1 doi:10.64898/2026.02.06.703989

    work page doi:10.64898/2026.02.06.703989v1 2026

  34. [35]

    [cited 2025 Sep 20]

    AOP Mapper [Internet]. [cited 2025 Sep 20]. Available from: enanomapper.adma.ai/aop/

    work page 2025

  35. [36]

    Brain-wide Electrical Spatiotemporal Dynamics Encode Depression Vulnerability

    Hultman R, Ulrich K, Sachs BD, Blount C, Carlson DE, Ndubuizu N, et al. Brain-wide Electrical Spatiotemporal Dynamics Encode Depression Vulnerability. Cell. 2018 Mar;173(1):166-180.e14. doi:10.1016/j.cell.2018.02.012

    work page doi:10.1016/j.cell.2018.02.012 2018

  36. [37]

    AOP-Wiki Metrics for AOP Scientific Review and OECD Endorsement [Internet]

    Hench V. AOP-Wiki Metrics for AOP Scientific Review and OECD Endorsement [Internet]. 2026 Feb 4 [cited 2026 May 19]. Available from: https://zenodo.org/records/20281512 doi:10.5281/zenodo.20281512

    work page doi:10.5281/zenodo.20281512 2026

  37. [38]

    agronholm/sqlacodegen [Python] [Internet]

    Grönholm A. agronholm/sqlacodegen [Python] [Internet]. 2026 [cited 2026 May 18]. Available from: https://github.com/agronholm/sqlacodegen

    work page 2026

  38. [39]

    Cross-species applicability of an adverse outcome pathway network for thyroid hormone system disruption

    Haigis AC, Vergauwen L, LaLone CA, Villeneuve DL, O’Brien JM, Knapen D. Cross-species applicability of an adverse outcome pathway network for thyroid hormone system disruption. Toxicol Sci. 2023 Sep 1;195(1):1–27. doi:10.1093/toxsci/kfad063

    work page doi:10.1093/toxsci/kfad063 2023

  39. [40]

    A high-throughput microphysiological system to quantify key events leading to liver fibrosis

    Schmidt S, Suter-Dick L. A high-throughput microphysiological system to quantify key events leading to liver fibrosis. Toxicology. 2025 Dec 1;518:154248. doi:10.1016/j.tox.2025.154248

    work page doi:10.1016/j.tox.2025.154248 2025

  40. [41]

    AOP Developers’ Handbook v2.8 [Internet]

    Villeneuve D, Meek B, Viviani B, Burgdorf T, LaLone C, O’Brien J, et al. AOP Developers’ Handbook v2.8 [Internet]. AOP-Wiki; 2026. Available from: aopwiki.org/handbooks/6

    work page 2026

  41. [42]

    EHS-Data-Standards/linkml-aop: A LinkML schema for Adverse Outcome Pathways [Internet]

    Caufield H, Hench VK. EHS-Data-Standards/linkml-aop: A LinkML schema for Adverse Outcome Pathways [Internet]. [cited 2026 Jan 22]. Available from: github.com/EHS-Data-Standards/linkml-aop

    work page 2026

  42. [43]

    Adverse outcome pathway networks II: Network analytics

    Villeneuve DL, Angrish MM, Fortin MC, Katsiadaki I, Leonard M, Margiotta-Casaluci L, et al. Adverse outcome pathway networks II: Network analytics. Environ Toxicol Chem. 2018;37(6):1734–48. doi:10.1002/etc.4124

    work page doi:10.1002/etc.4124 2018

  43. [44]

    Transformations Underway in the AOP-Knowledgebase and Wiki to Advance NAMs [Internet]

    Hench V. Transformations Underway in the AOP-Knowledgebase and Wiki to Advance NAMs [Internet]. 2024 Apr 22 [cited 2026 May 18]. Available from: https://zenodo.org/records/20273388 doi:10.5281/zenodo.20273388

    work page doi:10.5281/zenodo.20273388 2024

  44. [45]

    Environmental Health Language Collective (EHLC) Adverse Outcome Pathway (AOP) Standards Workshop Report [Internet]

    Environmental Health Language Collective. Environmental Health Language Collective (EHLC) Adverse Outcome Pathway (AOP) Standards Workshop Report [Internet]. doi:doi.org/10.5281/zenodo.17903427

    work page doi:10.5281/zenodo.17903427

  45. [46]

    The Environmental Health Language Collaborative (EHLC) Adverse Outcome Pathway (AOP) Standards Workshop Report [Internet]

    Mortensen H, Hench V, Nymark P, Lynn S, Hogberg H, Feshuk M, et al. The Environmental Health Language Collaborative (EHLC) Adverse Outcome Pathway (AOP) Standards Workshop Report [Internet]. F1000Research; 2026 [cited 2026 May 20]. Available from: https://f1000research.com/articles/15-323 doi:10.12688/f1000research.175826.1

    work page doi:10.12688/f1000research.175826.1 2026

  46. [47]

    Providing Adverse Outcome Pathways from the AOP-Wiki in a Semantic Web Format to Increase Usability and Accessibility of the Content

    Martens M, Evelo CT, Willighagen EL. Providing Adverse Outcome Pathways from the AOP-Wiki in a Semantic Web Format to Increase Usability and Accessibility of the Content. Appl Vitro Toxicol. 2022 Mar;8(1):2–13. doi:10.1089/aivt.2021.0010

    work page doi:10.1089/aivt.2021.0010 2022

  47. [48]

    AOPWIKI-EXPLORER: An interactive graph-based query engine leveraging large language models

    Kumar S, Deepika D, Slater K, Kumar V. AOPWIKI-EXPLORER: An interactive graph-based query engine leveraging large language models. Comput Toxicol. 2024 Jun 1;30:100308. doi:10.1016/j.comtox.2024.100308

    work page doi:10.1016/j.comtox.2024.100308 2024

  48. [49]

    US EPA [Data and Tools] [Internet]

    Edwards SW. US EPA [Data and Tools] [Internet]. 2016 [cited 2026 May 20]. Adverse Outcome Pathway Knowledge Base. Available from: https://19january2021snapshot.epa.gov/chemical-research/adverse-outcome-pathway-knowledge-base-0 Figures Figure 1: AOP Framework Properties and AOP-Wiki EMOD Data Model Expansions. A) Core aspects of the AOP framework. B) AOP-W...

    work page 2016